Amphastar Pharmaceuticals, Inc. (AMPH) stock
AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3033% below fair value
$28.60−0.46 (-1.58%)
Close on Nov 11, 2026Market cap $1.22BP/E 13.0Yield –
Amphastar Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Amphastar Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2024 was $260.12M, up 29.8% year over year. For fiscal 2023 it was $222.72M, up 85.5% from the year before. The highest annual figure on record is $222.72M in fiscal 2023.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $222.72M | +85.5% |
| FY2022 | Dec 31, 2022 | $120.09M | +49.9% |
| FY2021 | Dec 31, 2021 | $80.11M | +300.9% |
| FY2020 | Dec 31, 2020 | $19.98M | +184.7% |
| FY2019 | Dec 31, 2019 | $7.02M | – |
| FY2018 | Dec 31, 2018 | -$2.57M | -149.9% |
| FY2017 | Dec 31, 2017 | $5.15M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $66.36M | -5.8% |
| Q2 FY2026 | Jun 30, 2026 | $54.04M | -21.0% |
| Q3 FY2025 | Sep 30, 2025 | $39.45M | -31.6% |
| Q2 FY2025 | Jun 30, 2025 | $56.80M | -10.7% |
| Q3 FY2024 | Sep 30, 2024 | $70.45M | -14.4% |
| Q2 FY2024 | Jun 30, 2024 | $68.37M | +71.1% |
| Q1 FY2024 | Mar 31, 2024 | $57.67M | +56.6% |
| Q4 FY2023 | Dec 31, 2023 | $63.64M | +54.2% |
| Q3 FY2023 | Sep 30, 2023 | $82.30M | +208.8% |
| Q2 FY2023 | Jun 30, 2023 | $39.96M | +43.6% |
| Q1 FY2023 | Mar 31, 2023 | $36.83M | +51.2% |
| Q4 FY2022 | Dec 31, 2022 | $41.27M | +53.7% |
| Q3 FY2022 | Sep 30, 2022 | $26.65M | -2.3% |
| Q2 FY2022 | Jun 30, 2022 | $27.82M | +110.8% |
| Q1 FY2022 | Mar 31, 2022 | $24.36M | +90.4% |
| Q4 FY2021 | Dec 31, 2021 | $26.85M | +399.2% |
| Q3 FY2021 | Sep 30, 2021 | $27.27M | +356.6% |
| Q2 FY2021 | Jun 30, 2021 | $13.20M | – |
| Q1 FY2021 | Mar 31, 2021 | $12.79M | +34.3% |
| Q4 FY2020 | Dec 31, 2020 | $5.38M | +195.1% |
| Q3 FY2020 | Sep 30, 2020 | $5.97M | +45.7% |
| Q2 FY2020 | Jun 30, 2020 | -$894.00K | -133.9% |
| Q1 FY2020 | Mar 31, 2020 | $9.53M | – |
| Q4 FY2019 | Dec 31, 2019 | $1.82M | – |
| Q3 FY2019 | Sep 30, 2019 | $4.10M | – |
| Q2 FY2019 | Jun 30, 2019 | $2.63M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.54M | – |
See a number that looks wrong?